---
schema_version: '1.0'
id: government-20260925-e1de7e
title: Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for
  Comments
content_kind: government-document
url: https://www.federalregister.gov/documents/2026/09/25/2026-19660/reauthorization-of-the-biosimilar-user-fee-act-public-meeting-request-for-comments
url_hash: e1de7e5e0a4360e96359de3cd80b38f7f8ba35274e8b51319ad5424c3fbc4b9c
canonical_url: https://www.federalregister.gov/documents/2026/09/25/2026-19660/reauthorization-of-the-biosimilar-user-fee-act-public-meeting-request-for-comments
source: us-federal-register
category: government/us
category_raw: Notice
country: us
region: us
tags: []
lang: en
published_at: '2026-09-25T00:00:00Z'
fetched_at: '2026-09-25T09:00:41.537811Z'
updated_at: '2026-09-25T10:00:34Z'
status: published
content_hash: 5075180aeb1accc84fd47d249ef97f3461a26461a67b47c822b129f1e3053508
content_changed_at: null
license_note: full
license_basis: public-domain-17usc105
body_available: false
attribution: 'Source: Office of the Federal Register, National Archives and Records
  Administration'
license_rule: source:us-federal-register
summary: The Food and Drug Administration (FDA, the Agency, or we) is hosting a hybrid
  public meeting to discuss proposed recommendations for the reauthorization of the
  Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 2028 through 2032. The BsUFA
  authorizes FDA to collect user fees to support the process for the review of biosimilar
  biological product applications. The current legislative authority for BsUFA expires
  in September 2027. At that time, new legislation will be required for FDA to continue
  collecting user fees in future fiscal years. Following discussions with the regulated
  industry and periodic consultations with public stakeholders, the Federal Food,
  Drug, and Cosmetic Act (the FD&C Act) directs FDA to publish the recommendations
  for the reauthorized program in the Federal Register, hold a meeting at which the
  public may present its views on such recommendations, and provide for a period of
  30 days for the public to provide written comments on such recommendations. FDA
  will then consider such public views and comments and revise such recommendations,
  as necessary.
summary_source: official
summary_en: The Food and Drug Administration (FDA, the Agency, or we) is hosting a
  hybrid public meeting to discuss proposed recommendations for the reauthorization
  of the Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 2028 through 2032.
  The BsUFA authorizes FDA to collect user fees to support the process for the review
  of biosimilar biological product applications. The current legislative authority
  for BsUFA expires in September 2027. At that time, new legislation will be required
  for FDA to continue collecting user fees in future fiscal years. Following discussions
  with the regulated industry and periodic consultations with public stakeholders,
  the Federal Food, Drug, and Cosmetic Act (the FD&C Act) directs FDA to publish the
  recommendations for the reauthorized program in the Federal Register, hold a meeting
  at which the public may present its views on such recommendations, and provide for
  a period of 30 days for the public to provide written comments on such recommendations.
  FDA will then consider such public views and comments and revise such recommendations,
  as necessary.
summary_omitted_reason: null
redistribution: true
keywords_en:
- Act
- ACT SAIKYO
- Biosimilar
- Comments
- Fee
- for
- force majeure notice
- Maharashtra Food and Drug Administration
- Meeting
- Public
- Public Health Groups
- public policy
- Reauthorization
- Request
- Superfeet
- the
- THE BLUE HEARTS
- United States government
- User
entities_en:
- name: ACT SAIKYO
  type: organization
- name: force majeure notice
  type: event
- name: Maharashtra Food and Drug Administration
  type: organization
- name: Public Health Groups
  type: organization
- name: Superfeet
  type: organization
- name: THE BLUE HEARTS
  type: organization
- name: User
  type: person
topics_en:
- public policy
- United States government
numeric_facts: []
provenance:
  doc_id: 2026-19660
  doc_id_scheme: fr_docnum
  issuer:
  - Health and Human Services Department
  - Food and Drug Administration
  doc_type: Notice
  subtype: null
  action: Notice of public meeting; request for comments.
  significant: null
entities:
- name: Maharashtra Food and Drug Administration
  type: organization
- name: force majeure notice
  type: event
- name: THE BLUE HEARTS
  type: organization
- name: User
  type: person
- name: Superfeet
  type: organization
- name: ACT SAIKYO
  type: organization
- name: Public Health Groups
  type: organization
key_facts: []
related: []
related_auto:
- name: Oracle
  type: organization
  weight: 1.0
- name: SFlix
  type: organization
  weight: 1.0
- name: Daily Report
  type: event
  weight: 1.0
- name: Multica
  type: organization
  weight: 1.0
- name: 夢メモリ統合
  type: event
  weight: 1.0
computed_at: '2026-09-25T10:00:33Z'
---

# Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments

## TL;DR
The Food and Drug Administration (FDA, the Agency, or we) is hosting a hybrid public meeting to discuss proposed recommendations for the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 2028 through 2032. The BsUFA authorizes FDA to collect user fees to support the process for the review of biosimilar biological product applications. The current legislative authority for BsUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collecting user fees in future fiscal years. Following discussions with the regulated industry and periodic consultations with public stakeholders, the Federal Food, Drug, and Cosmetic Act (the FD&C Act) directs FDA to publish the recommendations for the reauthorized program in the Federal Register, hold a meeting at which the public may present its views on such recommendations, and provide for a period of 30 days for the public to provide written comments on such recommendations. FDA will then consider such public views and comments and revise such recommendations, as necessary.

## Key Points
- (なし)

## Details
(本文なし。リンク先参照)

## Source
元記事: [Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments](https://www.federalregister.gov/documents/2026/09/25/2026-19660/reauthorization-of-the-biosimilar-user-fee-act-public-meeting-request-for-comments) — published 2026-09-25T00:00:00Z
